Skip to content

Remote Cardiac Rehab for Adolescents With Congenital Heart Disease

Remotely Delivered Cardiac Rehabilitation for Adolescents With Congenital Heart Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06015191
Acronym
Remote-CaRe
Enrollment
74
Registered
2023-08-29
Start date
2023-08-31
Completion date
2027-12-01
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Disease in Children

Keywords

Exercise, Cardiac Rehabilitation, Physical Activity, Telehealth

Brief summary

The goal of this randomized controlled trial is to evaluate the effectiveness of video conferencing for the delivery of live-supervised, real-time cardiac rehabilitation (CR) exercise training to groups of adolescents with congenital heart disease (CHD) in their homes. Participants will be randomized to either the remote cardiac rehab (RCR) group or active control group. The RCR group will participate in live, group-based exercise training (3-5 participants per exercise session), in their homes 3 days per week for 45 minutes over 12-weeks. Exercise sessions will be led and supervised by a live health coach via telehealth video technology. The active control group will be provided informational handouts on health exercise for their cardiac diagnosis. The primary aim is to compare between group changes (0-12-weeks) in cardiorespiratory fitness (VO2peak). Secondary aims are to compare between group changes (0-12-weeks) in cardiac function (echocardiography), lean body mass, and physical frailty. Exploratory aims will compare between group changes (0-12-weeks) in physical function, quality of life, skeletal muscle function, and physical activity self-efficacy. Additionally, exploratory aims will explore the impact of demographic characteristics, program participation, program satisfaction, and daily physical activity on changes in cardiorespiratory fitness.

Detailed description

This randomized controlled trial will evaluate the effectiveness of live, in-home, group-based cardiac rehabilitation (CR) exercise training compared to standard care (active) control. Participants will include adolescents (age 12-19 years) with one of three congenital heart disease (CHD) diagnoses: Fontan (single ventricle) circulation, Tetralogy of Fallot, or dextro-transposition of the great vessels. Following baseline outcomes testing, participants will be computer randomized (with equal stratification by CHD diagnosis and biologic sex) to either the remote cardiac rehab (RCR) group (n=\ 37) or the active control group (n=\ 37). Participants randomized to the RCR group will participate in 12-weeks of live-supervised exercise training (36 sessions total) from their respective homes led by a trained health coach via telehealth video technology. RCR participants will initially engage in a 2-week ramp-up period (1-1 or small groups, 6-sessions total) with a live health coach, followed by 10-weeks of group-based (3-5 participants, 30 sessions total) exercise training where participants will be able to interact with the health coach and other participants. Participants in the RCR group will be asked to attend and participate in exercise sessions 3 days per week for 45-minutes. Exercise session intensity will be consistent with a heart rate of 60-75% of their VO2peak, will consist of a mix of flexibility, aerobic, and anaerobic exercise, and will be facilitated by a small set of exercise equipment (e.g., resistance bands, cones, medicine balls) provided to participants. Participants randomized to the active control group will be provided handouts that describe exercises consistent with the physical activity recommendations for youth. The total intervention period for both groups will be 12-weeks. Primary, secondary, and exploratory outcomes will be measured at baseline and 12-13-weeks following randomization. Additionally, participants in both groups will be provided a consumer grade wrist-worn physical activity monitor, where participants will be encouraged to wear throughout the 12-week intervention period and beyond for a minimum of 6-months. Participants randomized to the active control group will be provided the opportunity to participate in the RCR exercise training once enrollment goals are met.

Interventions

Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.

BEHAVIORALActive Control

Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.

Sponsors

Children's Mercy Hospital Kansas City
Lead SponsorOTHER
University of Kansas
CollaboratorOTHER
Children's Hospital of Philadelphia
CollaboratorOTHER
University of North Carolina, Chapel Hill
CollaboratorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Randomized Controlled Trial

Eligibility

Sex/Gender
ALL
Age
12 Years to 19 Years
Healthy volunteers
No

Inclusion criteria

1. Age 12-19 years old 2. Male or Female 3. Diagnosed with one of three congenital heart diseases: Univentricular heart with Fontan Palliation Tetralogy of Fallot with transannular patch Dextro-transposition of the great arteries with arterial switch operation 4. Primary Cardiology clearance for exercise participation 5. Internet access in their homes 6. Available for in-home exercise between 4-7pm on at least 3 days of the Monday-Friday work week 7. English Speaking 8. Achieving maximal effort on a cardiopulmonary exercise test, defined as RER ≥1.1 and/or in the judgement of the supervising exercise physiologist, a maximal effort was achieved but exercise capacity is limited by musculoskeletal deconditioning.

Exclusion criteria

1. Physically or developmentally unable to perform outcomes assessments or participate in moderate-to-vigorous intensity physical activity 2. Participating in \> 15 MET-hours per week (mean weekly average over the past 12-months) of organized athletic/exercise activity (not including school physical education class). 3. Height less than 132cm 4. Pregnancy or planned surgery or procedure (excluding outpatient, non-cardiac procedures) within the 12-week study period. 5. Meeting at least 1 exercise test safety or screening criteria on most recent exercise test (pre-study) or baseline outcomes visit exercise test 6. Presence of significant cardiac dysfunction that would impair safe participation in moderate-to-vigorous intensity exercise 7. Significant changes baseline echocardiogram or most recent clinical echocardiogram (from past clinical echocardiogram) such as decrease in ventricular and/or valvar function, new obstruction, or any new structural abnormalities 8. Uncontrolled or poorly controlled asthma 9. Presence of implanted cardioverter-defibrillator 10. Pacemaker with rate-responsive function initiated 11. Reliance on ventricular assist device 12. Prescribed milrinone medication 13. Listed for heart transplantation 14. Active engagement in hormone replacement for gender transition

Design outcomes

Primary

MeasureTime frameDescription
Peak Cardiorespiratory FitnessChange from baseline to 12-weeksCardiorespiratory fitness will be assessed using a peak cardiopulmonary exercise stress test (VO2peak) on a cycle ergometer using a ramping cycle protocol.

Secondary

MeasureTime frameDescription
Echocardiogram with global longitudinal strain (Fontan)Change from baseline to 12-weeksCardiac Function for the participant with Fontan diagnosis will be assessed with echocardiogram using greyscale 2-dimensional images obtained of the single left ventricle, right ventricle or the entirety of the biventricular morphology. Global longitudinal strain analysis will be performed by averaging the apical 4, 3, or 2 images using GE EchoPAC BT13 software following American Society of Echocardiography guidelines.
Echocardiogram with global longitudinal strain (Tetralogy of Fallot and d-transposition of the great vessels)Change from baseline to 12-weeksCardiac Function for the participant with Tetralogy of Fallot and d-transposition of the great vessels diagnosis will be assessed with echocardiogram using greyscale 2-dimensional images obtained on the ventricles. Global longitudinal strain analysis will be performed by averaging the apical 4, 3, and 2 images using GE EchoPAC BT13 software following American Society of Echocardiography guidelines.
Lean Body MassChange from baseline to 12-weeksBody composition will be assessed using whole-body dual energy X-ray absorptiometry (DXA)
Frailty (slowness)Change from baseline to 12-weeksSlowness will be assessed using a 6-minute walk test
Frailty (weakness)Change from baseline to 12-weeksWeakness will be assessed using handgrip strength dynamometry.
Frailty (fatigue)Change from baseline to 12-weeksFatigue will be assessed using the Pediatric quality of life inventory (PedsQL) Multidimensional Fatigue Scale (Range: 0 (high fatigue) - 100 (low fatigue))
Frailty (energy expenditure/physical activity)Change from baseline to 12-weeksPhysical activity / energy expenditure will be assessed using the self-report, past-week Physical Activity Questionnaire for Adolescents (PAQ-A) (Range: 1 (inactive) - 5 (highly active))
Functional MovementChange from baseline to 12-weeksFunctional Movement / gross motor proficiency will be assessed with the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2) (Range: -3SD (well-below average) - +4SD (well-above average)) SD = Standard deviations
Quality of Life Generic Core ScaleChange from baseline to 12-weeksQuality of life (QoL) will be assessed with the Pediatric Quality of Life inventory (PedsQL) Generic Core Scale (Range: 0 (low QoL) - 100 (high QoL))
Quality of Life Cardiac ModuleChange from baseline to 12-weeksCardiac specific quality of life (QoL) will be assessed with the Pediatric Quality of Life inventory (PedsQL) Cardiac Module (Range: 0 (low QoL) - 100 (high QoL))
Physical Activity Self-EfficacyChange from baseline to 12-weeksPhysical activity (PA) self-efficacy will be assessed using the Domain-Specific Physical Activity Efficacy Questionnaire (mean score of 0 (low PA self-efficacy) - 100 (high PA self-efficacy)
Exercise session adherence (Remote Cardiac Rehab Group)Baseline to 12-weeksExercise session adherence will be assessed using a wrist-worn Fitbit Versa 4 or Garmin Vivoactive 5 activity monitor. The Fitbit Versa 4 or Garmin Vivoactive 5 will be used to asses exercise heart rates during the exercise sessions.
Lifestyle Physical ActivityChange from baseline to 12-weeks and change from 12-weeks to 6-months post interventionPhysical activity will be assessed using a wrist-worn Fitbit Versa 4 or Garmin Vivoactive 5 activity monitor. The Fitbit Versa 4 or Garmin Vivoactive 5 will be used to determine the volume of physical activity participation in free-living conditions.

Countries

United States

Contacts

CONTACTMadeline Donnelli, BS
Remotecare@cmh.edu816-764-5605
CONTACTDavid Cloutier, MS, MBA
dacloutier@cmh.edu816-302-3636
PRINCIPAL_INVESTIGATORDavid A White, PhD

Children's Mercy Kansas City

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026